751 related articles for article (PubMed ID: 30023003)
1. Adding ezetimibe to statin therapy: latest evidence and clinical implications.
Vavlukis M; Vavlukis A
Drugs Context; 2018; 7():212534. PubMed ID: 30023003
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Jamialahmadi T; Baratzadeh F; Reiner Ž; Simental-Mendía LE; Xu S; Susekov AV; Santos RD; Sahebkar A
Mediators Inflamm; 2021; 2021():9661752. PubMed ID: 34526854
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors.
Choi JY; Na JO
J Lipid Atheroscler; 2019 Sep; 8(2):183-191. PubMed ID: 32821708
[TBL] [Abstract][Full Text] [Related]
4. Role of colesevelam in combination lipid-lowering therapy.
Jones MR; Nwose OM
Am J Cardiovasc Drugs; 2013 Oct; 13(5):315-23. PubMed ID: 23913404
[TBL] [Abstract][Full Text] [Related]
5. Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus.
Saag JL; Gross D; Stirt D; Espina Rey A; Gros B
Cureus; 2023 Jun; 15(6):e40905. PubMed ID: 37492827
[TBL] [Abstract][Full Text] [Related]
6. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
7. Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses.
Shaya FT; Sing K; Milam R; Husain F; Del Aguila MA; Patel MY
Am J Cardiovasc Drugs; 2020 Jun; 20(3):239-248. PubMed ID: 31724105
[TBL] [Abstract][Full Text] [Related]
8. Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.
Lee SJ; Cha JJ; Choi WG; Lee WS; Jeong JO; Choi S; Cho YH; Park W; Yoon CH; Lee YJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Hong SJ; Kim JS;
JAMA Cardiol; 2023 Sep; 8(9):853-858. PubMed ID: 37531130
[TBL] [Abstract][Full Text] [Related]
9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
10. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.
Ara R; Tumur I; Pandor A; Duenas A; Williams R; Wilkinson A; Paisley S; Chilcott J
Health Technol Assess; 2008 May; 12(21):iii, xi-xiii, 1-212. PubMed ID: 18485273
[TBL] [Abstract][Full Text] [Related]
12. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
Reiner Ž
Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
[TBL] [Abstract][Full Text] [Related]
13. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
14. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
Adhyaru BB; Jacobson TA
Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
[TBL] [Abstract][Full Text] [Related]
15. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature.
Yu M; Liang C; Kong Q; Wang Y; Li M
Lipids Health Dis; 2020 Jan; 19(1):1. PubMed ID: 31900179
[TBL] [Abstract][Full Text] [Related]
18. Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA): A randomized clinical trial.
Lv X; Liu X; Peng Y; Li W; Wang J; Chen X; Lei J; Tang C; Luo S; Mai W; Cai Y; Fan Q; Liu C; Zhang L
J Stroke Cerebrovasc Dis; 2024 May; 33(5):107647. PubMed ID: 38431112
[TBL] [Abstract][Full Text] [Related]
19. Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia.
Lee J; Lee SH
Korean J Intern Med; 2023 Nov; 38(6):797-809. PubMed ID: 37866817
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
